The new frontier for oncology
Tuesday 10th June, 13:00, Basel Marriott Hotel, Messepl. 25, 4058 Basel, Switzerland
Details & Registration Form: please scroll to the bottom of this page to complete the form or click here
Executive Summary
Scientific breakthroughs and impactful progression of new technological advancements have created new hope for oncology patients, with precision medicine enabling very targeted therapies and further supported by patient centric drug delivery technologies such as single or multi-use devices and wearable technologies, freeing patients from the burdens of in-clinic administration.
Join PCI and partner companies Ypsomed, Worldwide Clinical Trials and ProBioGen for an informative session on the rapidly advancing frontier of new oncology pathways such as Antibody Drug Conjugates (ADC’s), oligonucleotides, radiopharmaceuticals, advanced biologics, and other rapidly advancing sciences, coupled with innovative new drug-device combination technologies, with example technologies at the forefront of breakthrough science. We will discuss the impact of these new medicines as we consider new paradigms for manufacturing and supply chain fulfillment in support of oncology patients around the world.
| 13:00 - Registration |
| 14:00 - Welcome & introduction |
| 14:15 - Breakthrough Science in Oncology: Engendering Hope Matt Cooper, PhD. Executive Director | Therapeutic Strategy Lead, Oncology. WorldWide Clinical Trials Breakthroughs in oncology research are transforming cancer care, with targeted therapies, immunotherapies, and precision medicine offering unprecedented potential for more effective, personalized treatments. Oncology remains the most active and competitive therapeutic area globally, with sponsors under pressure to not only innovate quickly, but to do so while navigating growing clinical, regulatory, and supply chain complexity. These scientific and technological advances are reshaping every stage of the product lifecycle—and success now hinges on the ability to integrate flexible operations, scalable manufacturing strategies, and agile logistics models that support the unique needs of oncology pipelines. What You’ll Learn • The latest trends and breakthroughs in oncology research and development • How scientific innovation is transforming trial design, execution, and patient access • Key challenges in global trial delivery—from regulatory requirements to manufacturing and clinical supply chain • Practical strategies for aligning drug development with the needs of both patients, regulators and investors • How to build operational resilience and flexibility in support of high-stakes oncology programs |
| 15:00 - The impact of new therapeutic pathways on drug substance and drug product manufacturing & supply chains Ron Chan, Business Development Executive, PCI Pharma Services & Michiel Stork, VP Business Development, ProBioGen Developing new therapeutics involves a multi-stage manufacturing process that often separates Drug Substance (DS) and Drug Product (DP) CDMO selection. Companies typically develop DS in-house or with a DS CDMO, while DP selection occurs later—introducing challenges such as time pressures, quality alignment (non-GMP vs. GMP-ready material), and coordination difficulties. The competitive landscape further complicates finding the right DP CDMO with the necessary expertise. Pre-established collaboration between DS and DP CDMOs, such as ProBiogen and PCI, helps mitigate these risks by streamlining communication, aligning project timelines, and reducing inefficiencies. Clients benefit from transparent project management, flexible agreement structures (single or separate contracts), and a cohesive approach to achieving first-in-human milestones. This coordinated strategy improves supply chain efficiency, de-risks development, and supports a smoother transition to scalable commercial supply. What You’ll Learn • How to anticipate and navigate common challenges in DS and DP manufacturing coordination. • The impact of early DS and DP integration on accelerating first-in-human timelines. • Real-world insights from ProBiogen and PCI on overcoming communication and process hurdles. • Best practices for structuring agreements to streamline CDMO partnerships. • Strategies to enhance efficiency, reduce risks, and optimize supply chain success. |
| 15:45 - How oncology breakthroughs are impacting clinical trial execution and logistics The global oncology pipeline continues to expand at pace, with over 2,000 oncology compounds in active development—more than any other therapeutic area. Breakthroughs in targeted therapies, immunotherapies, and precision medicine are offering new hope to patients but also introducing greater complexity to clinical trial execution. These scientific advancements are driving a need for adaptive trial designs, smarter regulatory planning, and agile supply chain solutions capable of meeting the demands of increasingly personalized, global studies. Sponsors must now navigate challenges such as patient recruitment in competitive landscapes, data complexity, and logistical coordination across multiple geographies. What You’ll Learn • How oncology breakthroughs are changing the expectations of clinical trial design and operations • Strategies to optimize logistics, distribution, and temperature-sensitive supply chains • Approaches to overcoming recruitment and retention challenges in oncology trials • Regulatory considerations for complex, global oncology studies • How to manage the growing complexity of data and decentralized trial models • Practical examples of integrated solutions that accelerate timelines and improve patient access |
| 16:30 - Transforming the patient experience: Innovations to provide safe and effective self-administration Justin Schroeder – Global Vice President, Technical Sales, PCI Pharma Services & Ralf Kuenzi – Account & Business Development Manager, YPSOMED The rise of drug-device combination products for self-administration has created both opportunities and challenges in ensuring a seamless, patient-friendly experience. Innovations in biopharmaceutical science and device technology are expanding the potential for broader application, including oncology therapies, while reshaping patient care. This session explores key considerations for optimizing self-administration, including injection frequency, tolerability, complexity, and adherence challenges across diverse patient populations. We will examine best practices in combination product design, user experience, and the evolving clinical-to-commercial journey—covering patient feedback, human factors, container/closure and device strategy, packaging and labeling, supply chain architecture, and sustainability. What You’ll Learn • Emerging trends in drug-device innovations and their impact on patient care. • Strategies to improve adherence and user experience in self-administered therapies. • Key design, packaging, and supply chain considerations for patient-friendly injectables. • The role of patient feedback and human factors in optimizing self-administration. • Balancing regulatory, commercial, and sustainability requirements in device strategy. |
| 17:15 - Drinks reception & buffet dinner |
Speakers
 | Justin Schroeder Justin is the Global Vice President of Technical Sales and is celebrating 25 years with PCI this year. During his tenure, Justin has held roles in engineering, design and development, program management, marketing, business development, strategy execution, and various global leadership positions within the company. In his current role, Justin is responsible for supporting clients in the earliest stages of program development and consideration, advising on aspects of device and packaging development, supply chain planning, and program management to navigate clinical and commercial stages. He holds a Bachelor's degree in Packaging Science from Michigan State University and a Master’s degree in Business Administration from Northern Illinois University. Justin is also a Certified Packaging Professional through the Institute of Packaging Professionals and has previously served on the Board of Directors for the Healthcare Compliance Packaging Council. Residing in the greater Chicago area, Justin is a husband and father of three teenagers, an avid runner, and someone who passionately loves spending time outdoors in nature at every opportunity. He is thrilled to be back in Switzerland! |
 | Ron Chan Ron is the Business Development Executive for PCI's Development & Manufacturing segment. With over 15 years of industry experience, he brings extensive expertise in the CDMO space, covering both sterile injectables and non-sterile oral dosage forms. Prior to joining PCI, Ron held global business development roles with drug substance CDMOs and manufacturers of critical medicines. Based in Hamburg, Germany, Ron is responsible for PCI's Drug Product Development & Manufacturing CDMO activities across the DACH, Nordic, and Eastern European regions. His focus is on driving new business to PCI’s manufacturing sites and fostering strategic, long-term partnerships. |
 | Michiel Stork After obtaining his Ph.D. in Molecular Microbiology, Michiel transitioned into the field of vaccinology, beginning with antigen discovery and animal models, followed by vaccine design, process development, and GMP manufacturing. This experience enabled him to work across the entire value chain - from lead discovery through to the production of clinical trial material. During his time as Head of Process Development at a CDMO, Michiel focused on process design, scale-up, and yield optimization. Alongside his technical responsibilities, he developed a strong interest in securing new projects, ultimately leading to a complete shift into business development. In early 2023, Michiel joined ProBioGen as Vice President of Business Development, expanding his focus to include therapeutic proteins. |
 | Matt Cooper Matt is the Executive Director, Therapeutic Strategy Lead, Oncology at Worldwide Clinical Trials. He brings over 20 years of oncology drug development experience across both the CRO and sponsor sides. His expertise spans solid tumors and hematologic malignancies, with a particular emphasis on early-phase development. Throughout his career, Matt has held various roles in clinical operations, project management, and program leadership. He is passionate about designing and executing strategic development plans that accelerate timelines and bring innovative therapies to patients faster. |
 | Ralf Kuenzi Ralf Kuenzi is a Director at Ypsomed, responsible for account management and business development, with a focus on strategic partnerships with key accounts and networking partners. Before rejoining Ypsomed in 2022, Ralf spent 10 years leading the ophthalmology and medical business segments at the primary packaging specialist Hoffmann Neopac. Prior to that, he held various roles in product management, key account management, and business development at Disetronic/Ypsomed for 16 years. Ralf has a professional background in life sciences and holds a diploma in Business Management from the Open University, UK. |
BIO2BUSINESS LTD. London BioScience Innovation Centre, 2 Royal College Street, London. NW1 0NH.
Contact us by phone on +44 (0)207 691 3568; or by e-mail at [email protected]
Bio2BEvents Home | BOS Media pack for 2024 events | BOS Media pack for 2025 events
